司美格鲁肽减肥针研发企业起诉Hims & Hers 后者推出49美元减肥丸产品

新浪财经02-09

来源：环球市场播报诺和诺德方面表示，公司已于2月9日对远程医疗服务商Hims & Hers提起联邦诉讼，指控该公司销售旗下爆款减肥药物司美格鲁肽减肥针的仿制品，涉嫌侵犯诺和诺德的专利。此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610350655?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-09 21:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610350655","market":"us","top_or_hot":-1,"title":"司美格鲁肽减肥针研发企业起诉Hims & Hers 后者推出49美元减肥丸产品","media":"新浪财经","content":"<div>\n<p>来源：环球市场播报诺和诺德方面表示，公司已于2月9日对远程医疗服务商Hims & Hers提起联邦诉讼，指控该公司销售旗下爆款减肥药物司美格鲁肽减肥针的仿制品，涉嫌侵犯诺和诺德的专利。此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>司美格鲁肽减肥针研发企业起诉Hims & Hers 后者推出49美元减肥丸产品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n司美格鲁肽减肥针研发企业起诉Hims & Hers 后者推出49美元减肥丸产品\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 21:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>来源：环球市场播报诺和诺德方面表示，公司已于2月9日对远程医疗服务商Hims & Hers提起联邦诉讼，指控该公司销售旗下爆款减肥药物司美格鲁肽减肥针的仿制品，涉嫌侵犯诺和诺德的专利。此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOH","symbol_name":"Novo Nordisk A/S B Shares ADRhedged","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b","article_id":"2610350655","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610350655","pubTimestamp":1770642252,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司遂于2月7日宣布，将停止销售这款司美格鲁肽减肥针复方仿制药。针对这起诉讼，Hims & Hers的代表尚未立即回应《今日美国》的相关问询。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","NVOX":"2倍做多NVO ETF-Defiance","HIMS":"Hims & Hers Health Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓"},"translate_title":"Semaglutide weight loss injection research and development company sues Hims & Hers, the latter launches $49 weight loss pill product","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVO":1.97,"NVOH":0.6,"HIMS":1.95},"content_text":"来源：环球市场播报诺和诺德方面表示，公司已于2月9日对远程医疗服务商Hims & Hers提起联邦诉讼，指控该公司销售旗下爆款减肥药物司美格鲁肽减肥针的仿制品，涉嫌侵犯诺和诺德的专利。此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司遂于2月7日宣布，将停止销售这款司美格鲁肽减肥针复方仿制药。诺和诺德以司美格鲁肽减肥针为品牌销售的司美格鲁肽药物，是目前唯一一款获批用于减肥的胰高血糖素样肽-1（GLP-1）口服制剂。司美格鲁肽同时也以司美格鲁肽降糖针为品牌，用于2型糖尿病患者的治疗。诺和诺德高级副总裁兼集团总法律顾问约翰・库克曼表示，本次诉讼是对Hims & Hers的全面追责，指控该远程医疗服务商“大规模营销未经批准的司美格鲁肽减肥针、司美格鲁肽降糖针仿制品，规避美国食药监局的黄金标准审查流程”。“这种行为对患者存在危险且具有欺骗性，还会破坏为保障这类疗法安全有效而建立的科学创新体系和严格监管机制。”诺和诺德指出，Hims & Hers目前仍在“非法大批量配制诺和诺德经美国食药监局批准的注射类药物的复方制剂”，该行为已将“患者的健康与福祉置于风险之中”。针对这起诉讼，Hims & Hers的代表尚未立即回应《今日美国》的相关问询。美国食药监局此前规定，当药品出现供应短缺时，允许复方药房销售药品仿制品。2025年2月，该局宣布司美格鲁肽的供应短缺问题已解决，并为针对仿制诺和诺德该款药物的复方药房及相关机构的执法行动设定了最后期限。2月6日，美国食药监局以质量、安全和疗效存在隐患为由，宣布计划限制Hims & Hers等企业及线上药房所销售的复方药物中使用的胰高血糖素样肽-1类原料。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610350655","isCrawlerRequest":true}